Halozyme Therapeutics (HALO) Total Liabilities (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Total Liabilities data on file, last reported at $2.5 billion in Q1 2026.

• On a quarterly basis, Total Liabilities rose 43.1% year-over-year to $2.5 billion in Q1 2026; TTM through Mar 2026 was $2.5 billion, a 43.1% increase from a year earlier, with the FY2025 full-year figure at $2.5 billion, up 45.71% from the prior year.
• Total Liabilities for Q1 2026 stood at $2.5 billion, down from $2.5 billion in the prior quarter.
• Over the last five years, Total Liabilities for HALO reached as high as $2.5 billion in Q4 2025 and fell as low as $1.2 billion in Q1 2022.
• Historically, Total Liabilities has averaged $1.8 billion across 5 years, with a median of $1.7 billion in 2024.
• Across the five-year window, Total Liabilities soared 73.65% in 2022 and dropped 11.86% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $1.7 billion in 2022, then dropped by 1.33% to $1.6 billion in 2023, then grew by 3.04% to $1.7 billion in 2024, then surged by 45.71% to $2.5 billion in 2025, then decreased by 0.95% to $2.5 billion in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $2.5 billion in Q1 2026, $2.5 billion in Q4 2025, and $1.7 billion in Q3 2025.